Efficacy and safety of canakinumab in Schnitzler syndrome: AÂ multicenter randomized placebo-controlled study

In this first placebo-controlled study, canakinumab was effective in patients with Schnitzler syndrome, and thus canakinumab may be further evaluated as a therapeutic option for this rare disease.